Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 1/2019

01-02-2019 | Review

A review on anti-adhesion therapies of bacterial diseases

Authors: Arezoo Asadi, Shabnam Razavi, Malihe Talebi, Mehrdad Gholami

Published in: Infection | Issue 1/2019

Login to get access

Abstract

Background

Infections caused by bacteria are a foremost cause of morbidity and mortality in the world. The common strategy of treating bacterial infections is by local or systemic administration of antimicrobial agents. Currently, the increasing antibiotic resistance is a serious and global problem. Since the most important agent for infection is bacteria attaching to host cells, hence, new techniques and attractive approaches that interfere with the ability of the bacteria to adhere to tissues of the host or detach them from the tissues at the early stages of infection are good therapeutic strategies.

Methods

All available national and international databanks were searched using the search keywords. Here, we review various approaches to anti-adhesion therapy, including use of receptor and adhesion analogs, dietary constituents, sublethal concentrations of antibiotics, and adhesion-based vaccines.

Results

Altogether, the findings suggest that interference with bacterial adhesion serves as a new means to fight infectious diseases.

Conclusion

Anti-adhesion-based therapies can be effective in prevention and treatment of bacterial infections, but further work is needed to elucidate underlying mechanisms.
Literature
1.
2.
Signoretto C, Canepari P, Stauder M, Vezzulli L, Pruzzo C. Functional foods and strategies contrasting bacterial adhesion. Curr Opin Biotechnol. 2012;23:160–7.CrossRefPubMed
3.
Ofek I, Hasty DL, Sharon N. Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol. 2003;38:181–91.CrossRefPubMed
4.
Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta (BBA) Gen Subj. 2006;1760:527–37.CrossRef
5.
Johnson-Henry KC, Pinnell LJ, Waskow AM, Irrazabal T, Martin A, Hausner M, et al. Short-chain fructo-oligosaccharide and inulin modulate inflammatory responses and microbial communities in Caco2-bbe cells and in a mouse model of intestinal injury. J Nutr. 2014;144:1725–33.CrossRefPubMed
6.
Bibel DJ, Aly R, Shinefield HR. Inhibition of microbial adherence by sphinganine. Can J Microbiol. 1992;38:983–5.CrossRefPubMed
7.
Sherman P, Boedeker E. Pilus-mediated interactions of the Escherichia coli strain RDEC-1 with mucosal glycoproteins in the small intestine of rabbits. Gastroenterology. 1987;93:734–43.CrossRefPubMed
8.
Pak J, Pu Y, Zhang Z-T, Hasty DL, Wu X-R. Tamm–Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem. 2001;276:9924–30.CrossRefPubMed
9.
Piotrowski J, Slomiany A, Murty V, Fekete Z, Slomiany B. Inhibition of Helicobacter pylori colonization by sulfated gastric mucin. Biochem Int. 1991;24:749–56.PubMed
10.
11.
Cozens D, Read RC. Anti-adhesion methods as novel therapeutics for bacterial infections. Expert Rev Anti-infect Ther. 2012;10:1457–68.CrossRefPubMed
12.
Quintero-Villegas MI, Aam BB, Rupnow J, Sørlie M, Eijsink VG, Hutkins RW. Adherence inhibition of enteropathogenic Escherichia coli by chitooligosaccharides with specific degrees of acetylation and polymerization. J Agric Food Chem. 2013;61:2748–54.CrossRef
13.
Ofek I, Doyle RJ. Common themes in bacterial adhesion. Bacterial adhesion to cells and tissues. Springer, Berlin 1994, pp. 513–61.CrossRef
14.
Miörner H, Johansson G, Kronvall G. Lipoteichoic acid is the major cell wall component responsible for surface hydrophobicity of group A streptococci. Infect Immun. 1983;39:336–43.PubMedPubMedCentral
15.
Sharon N. Bacterial lectins, cell-cell recognition and infectious disease. FEBS Lett. 1987;217:145–57.CrossRefPubMed
16.
Cundell DR, Gerard NP, Craig G, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995;377:435.CrossRefPubMed
17.
Chen SL, Hung C-S, Xu J, Reigstad CS, Magrini V, Sabo A, et al. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci. 2006;103:5977–82.
18.
Svensson A, Larsson A, Emtenäs H, Hedenström M, Fex T, Hultgren SJ, et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem. 2001;2:915–8.CrossRefPubMed
19.
Pinkner JS, Bengtsson C, Edvinsson S, Cusumano CK, Rosenbaum E, Johansson LB, et al. Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms. Chem A Eur J. 2012;18:4522–32.CrossRef
20.
Hartlova A, Cerveny L, Hubalek M, Krocova Z, Stulik J. Membrane rafts: a potential gateway for bacterial entry into host cells. Microbiol Immunol. 2010;54:237–45.CrossRefPubMed
21.
Svensson M, Frendeus B, Butters T, Platt F, Dwek R, Svanborg C. Glycolipid depletion in antimicrobial therapy. Mol Microbiol. 2003;47:453–61.CrossRefPubMed
22.
Margalit M, Ash N, Zimran A, Halkin H. Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher’s disease. Postgrad Med J. 2002;78:564–5.CrossRefPubMedPubMedCentral
23.
Bernbom N, Jørgensen RL, Ng Y, Meyer R, Kingshott P, Vejborg RM, et al. Bacterial adhesion to stainless steel is reduced by aqueous fish extract coatings. Biofilms. 2006;3:25–36.CrossRef
24.
25.
Svensson M, Platt FM, Svanborg C. Glycolipid receptor depletion as an approach to specific antimicrobial therapy. FEMS Microbiol Lett. 2006;258:1–8.CrossRefPubMed
26.
Okuda K, Hanada N, Usui Y, Takeuchi H, Koba H, Nakao R, et al. Inhibition of Streptococcus mutans adherence and biofilm formation using analogues of the SspB peptide. Arch Oral Biol. 2010;55:754–62.CrossRefPubMed
27.
Moon HW, Bunn TO. Vaccines for preventing enterotoxigenic Escherichia coli infections in farm animals. Vaccine. 1993;11:213–20.CrossRefPubMed
28.
Sharon N, Ofek I. Safe as mother’s milk: carbohydrates as future anti-adhesion drugs for bacterial diseases. Glycoconj J. 2000;17:659–64.CrossRefPubMed
29.
Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol. 2005;55:441–55.CrossRefPubMed
30.
Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, et al. Antiadhesion therapy for urinary tract infections. A balanced PK/PD profile proved to be key for success. J Med Chem. 2012;55:4700–13.CrossRefPubMed
31.
Vanwetswinkel S, Volkov AN, Sterckx YG, Garcia-Pino A, Buts L, Vranken WF, et al. Study of the structural and dynamic effects in the FimH adhesin upon α-d-heptyl mannose binding. J Med Chem. 2014;57:1416–27.CrossRefPubMed
32.
Almant M, Moreau V, Kovensky J, Bouckaert J, Gouin SG. Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl α-d-Mannoside probes with a carbohydrate core. Chem A Eur J. 2011;17:10029–38.CrossRef
33.
Chemani C, Imberty A, de Bentzmann S, Pierre M, Wimmerová M, Guery BP, et al. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect Immun. 2009;77:2065–75.CrossRefPubMedPubMedCentral
34.
Ukkonen P, Varis K, Jernfors M, Herva E, Jokinen J, Ruokokoski E, et al. Treatment of acute otitis media with an antiadhesive oligosaccharide: a randomised, double-blind, placebo-controlled trial. Lancet. 2000;356:1398–402.CrossRefPubMed
35.
Lillehoj EP, Kim BT, Kim KC. Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am J Physiol Lung Cell Mol Physiol. 2002;282:L751-L6.CrossRef
36.
Ma J, Hunjan M, Smith R, Lehner T. Specificity of monoclonal antibodies in local passive immunization against Streptococcus mutans. Clin Exp Immunol. 1989;77:331.PubMedPubMedCentral
37.
Munro GH, Evans P, Todryk S, Buckett P, Kelly CG, Lehner T. A protein fragment of streptococcal cell surface antigen I/II which prevents adhesion of Streptococcus mutans. Infect Immun. 1993;61:4590–8.PubMedPubMedCentral
38.
Krachler AM, Mende K, Murray C, Orth K. In vitro characterization of multivalent adhesion molecule 7-based inhibition of multidrug-resistant bacteria isolated from wounded military personnel. Virulence. 2012;3:389–99.CrossRefPubMedPubMedCentral
39.
Lalezari JP, Henry K, O’hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–85.CrossRefPubMed
40.
Kumar Malik D, Baboota S, Ahuja A, Hasan S, Ali J. Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv. 2007;4:141–51.CrossRef
41.
Eucker TP, Konkel ME. The cooperative action of bacterial fibronectin-binding proteins and secreted proteins promote maximal Campylobacter jejuni invasion of host cells by stimulating membrane ruffling. Cell Microbiol. 2012;14:226–38.CrossRefPubMed
42.
Kelly CG, Lehner T. Peptide inhibitors of Streptococcus mutans in the control of dental caries. Int J Pept Res Ther. 2007;13:517–23.CrossRef
43.
Labrecque J, Bodet C, Chandad F, Grenier D. Effects of a high-molecular-weight cranberry fraction on growth, biofilm formation and adherence of Porphyromonas gingivalis. J Antimicrob Chemother. 2006;58:439–43.CrossRefPubMed
44.
Burger O, Weiss E, Sharon N, Tabak M, Neeman I, Ofek I. Inhibition of Helicobacter pylori adhesion to human gastric mucus by a high-molecular-weight constituent of cranberry juice. Crit Rev Food Sci Nutr. 2002;42:279–84.CrossRefPubMed
45.
46.
Klemm P, Vejborg RM, Hancock V. Prevention of bacterial adhesion. Appl Microbiol Biotechnol. 2010;88:451–9.CrossRefPubMed
47.
Ghosh S, Chakraborty K, Nagaraja T, Basak S, Koley H, Dutta S, et al. An adhesion protein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development. Proc Natl Acad Sci. 2011;108:3348–53.
48.
Bravo D, Blondel CJ, Hoare A, Leyton L, Valvano MA, Contreras I. Type IV B pili are required for invasion but not for adhesion of Salmonella enterica serovar Typhi into BHK epithelial cells in a cystic fibrosis transmembrane conductance regulator-independent manner. Microbial Pathog. 2011;51:373–7.CrossRef
49.
Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997;276:607–11.CrossRefPubMed
50.
Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;1996:341–9.CrossRef
51.
Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines. 2007;6:47–56.CrossRefPubMed
52.
Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, Huebner RC, et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun. 2000;68:796–800.CrossRefPubMedPubMedCentral
53.
Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis. 2008;198:571–5.CrossRefPubMedPubMedCentral
54.
Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis. 2001;7:92.CrossRefPubMedPubMedCentral
55.
Maiden MC, Stuart JM, Group UMC. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359:1829–30.CrossRefPubMed
56.
Evans CM, Pratt CB, Matheson M, Vaughan TE, Findlow J, Borrow R, et al. Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against N. meningitidis. Clin Infect Dis. 2011;52:70–7.CrossRefPubMed
57.
Kenny B, DeVinney R, Stein M, Reinscheid DJ, Frey EA, Finlay BB. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell. 1997;91:511–20.CrossRefPubMed
58.
Zhang C, Zhang W. Escherichia coli K88ac fimbriae expressing heat-labile and heat-stable (STa) toxin epitopes elicit antibodies that neutralize cholera toxin and STa toxin and inhibit adherence of K88ac fimbrial E. coli. Clin Vaccine Immunol. 2010;17:1859–67.CrossRefPubMedPubMedCentral
59.
Sheth H, Glasier L, Ellert N, Cachia P, Kohn W, Lee K, et al. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Biomed Pept Proteins Nucl Acids 1995;1:141–8.
60.
Arciola CR, Speziale P, Montanaro L. Perspectives on DNA vaccines. Targeting staphylococcal adhesins to prevent implant infections. Int J Artif Organs. 2009;32:635–41.CrossRefPubMed
61.
Therrien R, Lacasse P, Grondin G, Talbot BG. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein. Vaccine. 2007;25:5053–61.CrossRefPubMed
62.
Rogers TJ, Paton JC. Therapeutic strategies for Shiga toxin-producing Escherichia coli infections. Expert Rev Anti-Infect Ther. 2009;7:683–6.CrossRefPubMed
63.
Pinkner JS, Remaut H, Buelens F, Miller E, Åberg V, Pemberton N, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci. 2006;103:17897–902.CrossRef
64.
Eidam O, Dworkowski FS, Glockshuber R, Grütter MG, Capitani G. Crystal structure of the ternary FimC–FimFt–FimDN complex indicates conserved pilus chaperone–subunit complex recognition by the usher FimD. FEBS Lett. 2008;582:651–5.CrossRefPubMed
65.
Ton-That H, Schneewind O. Anchor structure of staphylococcal surface proteins IV. Inhibitors of the cell wall sorting reaction. J Biol Chem. 1999;274:24316–20.CrossRefPubMed
66.
Mortensen NP, Fowlkes JD, Maggart M, Doktycz MJ, Nataro JP, Drusano G, et al. Effects of sub-minimum inhibitory concentrations of ciprofloxacin on enteroaggregative Escherichia coli and the role of the surface protein dispersin. Int J Antimicrob Agents. 2011;38:27–34.CrossRefPubMed
67.
Wojnicz D, Jankowski S. Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains. Int J Antimicrob Agents. 2007;29:700–4.CrossRefPubMed
68.
Fonseca A, Sousa J. Effect of antibiotic-induced morphological changes on surface properties, motility and adhesion of nosocomial Pseudomonas aeruginosa strains under different physiological states. J Appl Microbiol. 2007;103:1828–37.CrossRefPubMed
69.
Roberts DE, Read RC, Cole PJ, Wilson R. Haemophilus influenzae infection of human respiratory mucosa in low concentrations of antibiotics. Am Rev Respir Dis. 1993;148:201–7.CrossRefPubMed
70.
Balagué C, Fernández L, Pérez J, Grau R. Effect of ciprofloxacin on adhesive properties of non-P mannose-resistant uropathogenic Escherichia coli isolates. J Antimicrob Chemother. 2003;51:401–4.CrossRefPubMed
71.
Rasigade JP, Moulay A, Lhoste Y, Tristan A, Bes M, Vandenesch F, et al. Impact of sub-inhibitory antibiotics on fibronectin-mediated host cell adhesion and invasion by Staphylococcus aureus. BMC Microbiol. 2011;11:263.CrossRefPubMedPubMedCentral
72.
Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis. 1991;74:23–33.
73.
Liu Y, Pinzón-Arango PA, Gallardo-Moreno AM, Camesano TA. Direct adhesion force measurements between E. coli and human uroepithelial cells in cranberry juice cocktail. Mol Nutr Food Res. 2010;54:1744–52.CrossRefPubMed
74.
Toivanen M, Huttunen S, Lapinjoki S, Tikkanen-Kaukanen C. Inhibition of adhesion of Neisseria meningitidis to human epithelial cells by berry juice polyphenolic fractions. Phytother Res. 2011;25:828–32.CrossRefPubMed
75.
Yamanaka A, Kimizuka R, Kato T, Okuda K. Inhibitory effects of cranberry juice on attachment of oral streptococci and biofilm formation. Mol Oral Microbiol. 2004;19:150–4.
76.
Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001;322:1571.CrossRefPubMedPubMedCentral
77.
Morrow AL, Ruiz-Palacios GM, Jiang X, Newburg DS. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. J Nutr. 2005;135:1304–7.CrossRefPubMed
78.
Coppa GV, Zampini L, Galeazzi T, Facinelli B, Ferrante L, Capretti R, et al. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediatr Res. 2006;59:377–82.CrossRefPubMed
79.
Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr. 2005;25:37–58.CrossRefPubMed
80.
Parker P, Sando L, Pearson R, Kongsuwan K, Tellam RL, Smith S. Bovine Muc1 inhibits binding of enteric bacteria to Caco-2 cells. Glycoconj J. 2010;27:89–97.CrossRefPubMed
81.
Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol. 2008;125:286–92.CrossRefPubMed
82.
Focareta A, Paton JC, Morona R, Cook J, Paton AW. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology. 2006;130:1688–95.CrossRefPubMed
83.
Lievin V, Peiffer I, Hudault S, Rochat F, Brassart D, Neeser J, et al. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut. 2000;47:646–52.CrossRefPubMedPubMedCentral
84.
Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 2000;78:80.CrossRefPubMed
85.
Moshiri M, Dallal MMS, Rezaei F, Douraghi M, Sharifi L, Noroozbabaei Z, et al. The effect of lactobacillus acidophilus PTCC 1643 on cultured intestinal epithelial cells infected with Salmonella enterica serovar Enteritidis. Osong Public Health Res Perspect. 2017;8:54.CrossRefPubMedPubMedCentral
86.
Cecioni S, Imberty A, Vidal S. Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands. Chem Rev. 2014;115:525–61.CrossRefPubMed
87.
Roberts PA, Huebinger RM, Keen E, Krachler A-M, Jabbari S. Predictive modelling of a novel anti-adhesion therapy to combat bacterial colonisation of burn wounds. arXiv preprint arXiv:170807062. 2017.
88.
Gholami M, Chirani AS, Razavi S, Falak R, Irajian G. Immunogenicity of a fusion protein containing PilQ and disulfide turn region of PilA from Pseudomonas aeruginosa in mice. Lett Appl Microbiol. 2017;65:439–445.CrossRef
89.
Campana R, Casettari L, Ciandrini E, Illum L, Baffone W. Chitosans inhibit the growth and the adhesion of Klebsiella pneumoniae and Escherichia coli clinical isolates on urinary catheters. Int J Antimicrob Agents. 2017;50:135–41.CrossRefPubMed
90.
Huttunen S, Toivanen M, Liu C, Tikkanen-Kaukanen C. Novel anti-infective potential of salvianolic acid B against human serious pathogen Neisseria meningitidis. BMC Res Notes. 2016;9:25.CrossRefPubMedPubMedCentral
91.
Raie DS, Mhatre E, Thiele M, Labena A, El-Ghannam G, Farahat LA, et al. Application of quercetin and its bio-inspired nanoparticles as anti-adhesive agents against Bacillus subtilis attachment to surface. Mater Sci Eng C. 2017;70:753–62.CrossRef
92.
Heana NY, Othmanb SNAM, Basarb N, Jemona K. Antibiofilm and antiadhesion activities of Phaleria macrocarpa against oral Streptococcus mutans. J Teknol. 2015;77:31–35.
93.
Miladi H, Mili D, Slama RB, Zouari S, Ammar E, Bakhrouf A. Antibiofilm formation and anti-adhesive property of three mediterranean essential oils against a foodborne pathogen Salmonella strain. Microbial Pathog. 2016;93:22–31.CrossRef
94.
Amerighi F, Valeri M, Donnarumma D, Maccari S, Moschioni M, Taddei A, et al. Identification of a monoclonal antibody against pneumococcal pilus 1 ancillary protein impairing bacterial adhesion to human epithelial cells. J Infect Dis. 2015;213:516–22.CrossRefPubMed
95.
Gupta D, Sarkar S, Sharma M, Thapa B, Chakraborti A. Inhibition of enteroaggregative Escherichia coli cell adhesion in-vitro by designed peptides. Microbial Pathog. 2016;98:23–31.CrossRef
96.
Boukerb AM, Rousset A, Galanos N, Mear J-B, Thepaut M, Grandjean T, et al. Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. J Med Chem. 2014;57:10275–89.CrossRefPubMed
97.
Kaspar KL, Howell AB, Khoo C. Ex vivo anti-adhesion activity of a proanthocyanidin standardized cranberry powder beverage. FASEB J. 2013;27:1079.42-.42.
98.
Fessele C, Lindhorst TK. Effect of aminophenyl and aminothiahexyl α-d-glycosides of the manno-, gluco-, and galacto-series on type 1 fimbriae-mediated adhesion of Escherichia coli. Biology. 2013;2:1135–49.CrossRefPubMedPubMedCentral
99.
Asha MK, Debraj D, Edwin JR, Srikanth H, Muruganantham N, Dethe SM, et al. In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action. J Ethnopharmacol. 2013;145:581–6.CrossRefPubMed
100.
Sumitomo T, Nakata M, Yamaguchi M, Terao Y, Kawabata S. S-carboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells. J Med Microbiol. 2012;61:101–8.CrossRefPubMed
101.
Stauder M, Papetti A, Mascherpa D, Schito AM, Gazzani G, Pruzzo C, et al. Antiadhesion and antibiofilm activities of high molecular weight coffee components against Streptococcus mutans. J Agric Food Chem. 2010;58:11662–6.CrossRefPubMed
102.
Howell AB, Botto H, Combescure C, Blanc-Potard A-B, Gausa L, Matsumoto T, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010;10:94.CrossRefPubMedPubMedCentral
103.
Burkholder KM, Bhunia AK. Salmonella enterica serovar Typhimurium adhesion and cytotoxicity during epithelial cell stress is reduced by Lactobacillus rhamnosus GG. Gut Pathog. 2009;1:14.CrossRefPubMedPubMedCentral
104.
Daglia M, Stauder M, Papetti A, Signoretto C, Giusto G, Canepari P, et al. Isolation of red wine components with anti-adhesion and anti-biofilm activity against Streptococcus mutans. Food Chem. 2010;119:1182–8.CrossRef
105.
Sinclair HR, Kemp F, de Slegte J, Gibson GR, Rastall RA. Carbohydrate-based anti-adhesive inhibition of Vibrio cholerae toxin binding to GM1-OS immobilized into artificial planar lipid membranes. Carbohydr Res. 2009;344:1968–74.CrossRefPubMed
106.
McEwan NA, Rème CA, Gatto H, Nuttall TJ. Monosaccharide inhibition of adherence by Pseudomonas aeruginosa to canine corneocytes. Vet Dermatol. 2008;19:221–5.CrossRefPubMed
107.
Rosentritt M, Hahnel S, Gröger G, Mühlfriedel B, Bürgers R, Handel G. Adhesion of Streptococcus mutans to various dental materials in a laminar flow chamber system. J Biomed Mater Res Part B Appl Biomater. 2008;86:36–44.CrossRefPubMed
108.
Gkana EN, Doulgeraki AI, Chorianopoulos NG, Nychas G-JE. Anti-adhesion and anti-biofilm potential of organosilane nanoparticles against foodborne pathogens. Front Microbiol. 2017;8:1295.CrossRefPubMedPubMedCentral
109.
Orooji Y, Faghih M, Razmjou A, Hou J, Moazzam P, Emami N, et al. Nanostructured mesoporous carbon polyethersulfone composite ultrafiltration membrane with significantly low protein adsorption and bacterial adhesion. Carbon. 2017;111:689–704.CrossRef
110.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269.CrossRefPubMedPubMedCentral
111.
112.
Tao Y, Pinzón-Arango PA, Howell AB, Camesano TA. Oral consumption of cranberry juice cocktail inhibits molecular-scale adhesion of clinical uropathogenic Escherichia coli. J Med Food. 2011;14:739–45.CrossRefPubMedPubMedCentral
113.
Herman-Bausier P, Valotteau C, Pietrocola G, Rindi S, Alsteens D, Foster TJ, et al. Mechanical strength and inhibition of the Staphylococcus aureus collagen-binding protein Cna. mBio. 2016;7:e01529-16.CrossRefPubMedPubMedCentral
114.
Valotteau C, Prystopiuk V, Pietrocola G, Rindi S, Peterle D, De Filippis V, et al. Single-cell and single-molecule analysis unravels the multifunctionality of the Staphylococcus aureus collagen-binding protein Cna. ACS Nano. 2017;11:2160–70.CrossRef
115.
Neto C, Penndorf K, Feldman M, Meron-Sudai S, Zakay-Rones Z, Steinberg D, et al. Characterization of non-dialyzable constituents from cranberry juice that inhibit adhesion, co-aggregation and biofilm formation by oral bacteria. Food Funct. 2017;8:1955–65.CrossRefPubMed
116.
Leshem R, Maharshak I, Jacob EB, Ofek I, Kremer I. The effect of nondialyzable material (NDM) cranberry extract on formation of contact lens biofilm by Staphylococcus epidermidis. Investig Ophthalmol Vis Sci. 2011;52:4929–34.CrossRef
117.
Sattin S, Bernardi A. Glycoconjugates and glycomimetics as microbial anti-adhesives. Trends Biotechnol. 2016;34:483–95.CrossRefPubMed
Metadata
Title
A review on anti-adhesion therapies of bacterial diseases
Authors
Arezoo Asadi
Shabnam Razavi
Malihe Talebi
Mehrdad Gholami
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2019
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1222-5

Other articles of this Issue 1/2019

Infection 1/2019 Go to the issue

Original Paper

Health-related quality of life in patients with alveolar echinococcosis: a cross-sectional study

Original Paper

Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab

Original Paper

Risk factors of bloodstream infections in recipients after liver transplantation: a meta-analysis

Case Report

Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide

Brief Report

A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults

Editorial

Sepsis: a frequent topic in a new Editorial Section in INFECTION
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits